[1]
|
Wu, J.N., Fish, K.M., Evans, C.P., White, R.W. and Dall’Era, M.A. (2014) No Improvement Noted in Overall or Cause-Specific Survival for Men Presenting with Metastatic Prostate Cancer over a 20-Year Period. Cancer, 120, 818-823. https://doi.org/10.1002/cncr.28485
|
[2]
|
Gravis, G., Fizzazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., et al. (2013) Androgen-Deprivation Therapy Alone or with Docetaxel in Non-Castrate Metastatic Prostate Cancer (GETUG-AFU 15): A Randomized, Open-Label, Phase 3 Trial. The Lancet Oncology, 14, 149-158. https://doi.org/10.1016/S1470-2045(12)70560-0
|
[3]
|
Sweeney, C.J., Chen, Y.H., Carducci, M., Liu, G., Jarrard, D.F., Eisenberger, M., et al. (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England Journal of Medicine, 373, 737-746. https://doi.org/10.1056/NEJMoa1503747
|
[4]
|
James, N.D., Sydes, M.R., Mason, M.D., Clarke, N.W., Anderson, J., Dearnaley, D.P., et al. (2015) Docetaxel and/or Zoledronic Acid for Hormone-Naïve Prostate Cancer: First Overall Survival Results from STAMPEDE (NCT00268476). Journal of Clinical Oncology, 33, 5001. https://doi.org/10.1200/jco.2015.33.15_suppl.5001
|
[5]
|
Mottet, N., van den Bergh, R.C.N., Briers, E., Bourke, L., et al. (2018) EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. 6.4.5.2 ADT Combined with Chemotherapy. 70. https://uroweb.org/wp-content/uploads/EAU-ESUR-ESTRO-SIOG-Guidelines-on-Prostate -Cancer-large-text-V2.pdf
|
[6]
|
Committee for Medicinal Products for Human Use (CHMP) Opinion “TAXOTERE in Combination with Androgen-Deprovation Therapy (ADT), with or without Prednisone or Prednisolone, Is Indicated for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer.” https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive -opinion-taxotere-ws-1550_en.pdf
|
[7]
|
Sun, G., Zhang, X., Chen, J., Liao, B., et al. (2018) What Kind of Patients with Castration-Naïve Prostate Cancer Can Benefit from Upfront Docetaxel and Abiraterone: A Systematic Review and a Network Meta-Analysis. Urologic Oncology, 36, 505-517. https://doi.org/10.1016/j.urolonc.2018.09.005
|
[8]
|
Gravis, G., Audenet, F., Irani, J., Timsit, M.O., et al. (2017) Chemotherapy in Hormone-Sensitive Metastatic Prostate Cancer: Evidences and Uncertainties from the Literature. Cancer Treatment Reviews, 55, 211-217. https://doi.org/10.1016/j.ctrv.2016.09.008
|
[9]
|
Akakura, K., Bruchovsky, N., Goldenberg, S.L., Rennie, P.S., Buckley, A.R. and Sullivan, L.D. (1993) Effects of Intermittent Androgen Suppression on Amdrogen-Dependent Tumors. Apoptosis and Serum Prostate-Specific Antigen. Cancer, 71, 2782-2790. https://doi.org/10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z
|
[10]
|
Huang, Y., Jiang, X., Liang, X. and Jiang, G. (2018) Molecular and Cellular Mechanism of Castration Resistant Prostate Cancer (Review). Oncology Letters, 15, 6063-6076. https://doi.org/10.3892/ol.2018.8123
|
[11]
|
Shore, N.D. (2013) Experience with Degarelix in the Treatment of Prostate Cancer. Therapeutic Advances in Urology, 5, 11-24. https://doi.org/10.1177/1756287212461048
|
[12]
|
Crawford, E.D., Schellhammer, P.F., McLeod, D.G., Moul, J.W., Higano, C.S., Shore, N., et al. (2018) Androgen Receptor Targeted Treatments of Prostate Cancer; 35 Years of Progress with Antiandrogens. Journal of Urology, 200, 956-966. https://doi.org/10.1016/j.juro.2018.04.083
|
[13]
|
Ryan, C.J., Smith, M.R., de Bono, J.S., Molina, A., Logothetis, C.J., de Souza, P., et al. (2013) Randomized Phase 3 Trial of Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer and No Prior Chemotherapy. New England Journal of Medicine, 368, 138-148.
|
[14]
|
Darshan, M.S., Loftus, M.S., Thadani-Mulero, M., Levy, B.P., Escuin, D., Zhou, X.K., et al. (2011) Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Response in Metastatic Prostate Cancer. Cancer Research, 71, 6019-6029. https://doi.org/10.1158/0008-5472.CAN-11-1417
|
[15]
|
Fizazi, K., Jenkins, C. and Tannock, I.F. (2015) Should Docetaxel Be Standard of Care for Patients with Metastatic Hormone-Sensitive Prostate Cancer? Pro and Contra. Annals of Oncology, 26, 1660-1667. https://doi.org/10.1093/annonc/mdv245
|
[16]
|
Shiota, M., Yokomizo, A. and Eto, M. (2016) Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy. Frontiers in Oncology, 5, 304. https://doi.org/10.3389/fonc.2015.00304
|
[17]
|
Ahmed, M. and Li, L.C. (2013) Adaptation and Clonal Selection Models of Castration-Resistant Prostate Cancer: Current Perspective. International Journal of Urology, 20, 362-371. https://doi.org/10.1111/iju.12005
|
[18]
|
Li, P., Yang, R. and Gao, W. (2014) Contributions of Epithelial-Mesenchymal Transition and Cancer Stem Cells to the Development of Castration Resistance of Prostate Cancer. Molecular Cancer, 13, 55. https://doi.org/10.1186/1476-4598-13-55
|
[19]
|
Martin, S.K., Kamelgarn, M. and Kyprianou, N. (2014) Cytosleleton Targeting Value in Prostate Cancer Treatment. American Journal of Clinical and Experimental Urology, 2, 15-26. https://pubmed.ncbi.nlm.nih.gov/25374905/
|
[20]
|
Zhu, M.L., Horbinski, C.M., Garzotto, M., Qian, D.Z., Beer, T.M. and Kyprianou, N. (2010) Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer. Cancer Research, 70, 7992-8002. https://doi.org/10.1158/0008-5472.CAN-10-0585
|
[21]
|
Jaworska, D. and Szliszka, E. (2017) Targeting Apoptotic Activity against Prostate Cancer Stem Cells. International Journal of Molecular Sciences, 18, 1648. https://doi.org/10.3390/ijms18081648
|
[22]
|
Eigl, B.J.C., Eggener, S.E., Baybik, J., Ettinger, S., Chi, K.N., Nelson, C., et al. (2005) Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather than Sequential Chemohormonal Therapy. Clinical Cancer Research, 11, 4905-4911. https://doi.org/10.1158/1078-0432.CCR-04-2140
|
[23]
|
Sasaki, T. and Sugimura, Y. (2018) The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients. Journal of Clinical Medicine, 7, 565. https://doi.org/10.3390/jcm7120565
|
[24]
|
Gravis, G., Boher, J.M., Chen, Y.H., et al. (2018) Burden of Metastatic Castrate Naïve Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analysis of CHAARTED and GETUG-AFU15 Studies. European Urology, 73, 847-855. https://doi.org/10.1016/j.eururo.2018.02.001
|